Skip to content

Swiss SOS MoCA - DCI Study

Impact of Delayed Cerebral Ischemia (DCI) on the Neuropsychological Outcome After Aneurysmal Subarachnoid Hemorrhage - a SWISS SOS Multicentre Observational Study

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03032471
Enrollment
128
Registered
2017-01-26
Start date
2017-07-20
Completion date
2022-05-06
Last updated
2022-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive Deficit, Cognitive Deficits Following Cerebral Infarction, Cognitive Deterioration, Cognitive Impairment, Complication, Delayed Cerebral Ischemia, Stroke, Subarachnoid Hemorrhage

Keywords

Subarachnoid Hemorrhage, Delayed cerebral ischemia, Cognitive Impairment, Montreal Cognitive Assessment, MoCA, Cognitive Deterioration

Brief summary

The primary objective of this multicenter observational study is to determine the effect size of the relationship between DCI and neuropsychological impairment 14-28 days and 3 months after aSAH. Secondary objectives are the feasibility to administer and the validity of the MoCA in an intensive care unit setting, as well as the test/retest reliability of the MoCA in patients with acute brain damage in absence of aSAH.

Detailed description

Background and rationale: Delayed cerebral ischemia (DCI) is the independent most important predictor of neurological disability in survivors following aneurysmal subarachnoid hemorrhage (aSAH). DCI could also be identified as the most important predictor of moderate to severe neuropsychological impairment following aSAH. Only few prospective studies so far specifically analyzed the effect size of the relationship between DCI and neuropsychological impairment, and all studies had a methodological weakness: lack of a baseline neuropsychological assessment before the onset of DCI. In studies analyzing the neuropsychological outcome after aSAH, the Montreal Cognitive Assessment (MoCA) is the most comprehensive, sensitive and specific instrument among the short tests. The MoCA is increasingly used in the aSAH population, while its validity and reliability has only been demonstrated in the normal population or patients suffering from diseases different from aSAH, such as e.g. Parkinson's disease or dementia. Today, neuropsychological examinations find entry into clinical routine for aSAH patients to estimate the need for inpatient rehabilitation. However, the MoCA is often applied to aSAH patients in a busy intensive or intermediate care unit, while it remains largely unknown whether the distraction in such an environment represents a bias to the obtained results. This study therefore evaluates aSAH patients before and after the phase of DCI, as well as three months after aSAH, in order to estimate the impact of DCI on neuropsychological impairment. In addition, the extent and location of cerebral ischemia, as measured with the Alberta Stroke Program Early CT Score (ASPECTS) is correlated with the neuropsychological outcome. Furthermore, the study measures the test/retest reliability of the MoCA, as well as the influence of the intensive care environment on the MoCA results in a randomized fashion in subjects with acute brain damage (and no aSAH). Objectives: The primary objective of this multicenter observational study is to determine the effect size of the relationship between DCI and neuropsychological impairment 14-28 days and 3 months after aSAH. Secondary objectives are the feasibility to administer and the validity of the MoCA in an intensive care unit setting, as well as the test/retest reliability of the MoCA in patients with acute brain damage in absence of aSAH. Outcomes: The primary endpoint is the proportion of patients with or without DCI that show worsening on the MoCA 3 months after the ictus as compared to before the DCI phase by at least two points. Key secondary endpoints for part 1 of the study are: * The proportion of patients with or without DCI that show worsening on the MoCA 14-28 days after the ictus as compared to before the DCI phase by at least two points. * The absolute difference of the MoCA before and after the active phase of DCI in patients with versus without DCI. * The absolute difference of the MoCA before the active phase of DCI and 3 months after aSAH in patients with versus without DCI * The rate of patients with versus without DCI that show cognitive impairment at 14-28 days and 3 months (defined as MoCA \< 26 points) * The correlation of neuropsychological outcome with the extent and location of ischemic lesions on brain CT-scan 12-21 days post-SAH, graded by the semi-quantitative ASPECT-grading * Health-related quality of life at 3 months in patients with versus without DCI * Home-time at 3 months in patients with versus without DCI * Death and dependency at 3 months in patients with versus without DCI * The absolute MoCA result, health-related quality of life and home-time at 3 months in patients with versus without hydrocephalus requiring shunting * The absolute MoCA result, health-related quality of life and home-time at 3 months in patients with surgical versus endovascular aneurysm occlusion Key secondary endpoints for part 2 of the study are: * The test/retest reliability of the MoCA in patients with acute brain damage * The influence of the intensive care environment on the MoCA in patients with acute brain damage

Interventions

OTHERThere is no intervention for this study. Patients are allocated to the study groups based on whether or not DCI occurs.

There is no intervention for this study. Patients are allocated to the study groups based on whether or not DCI occurs.

Sponsors

Insel Gruppe AG, University Hospital Bern
CollaboratorOTHER
Département des Neurosciences cliniques, Service de Neurochirurgie, Hôpitaux Universitaires de Genève
CollaboratorUNKNOWN
Primario Neurochirurgia, EOC Ospedale Regionale di Lugano - Civico e Italiano
CollaboratorUNKNOWN
Cantonal Hospital of St. Gallen
CollaboratorOTHER
Klinik für Neurochirurgie, Universitätsspital Zürich
CollaboratorUNKNOWN
Primario Neurologia, EOC Ospedale Regionale di Lugano - Civico e Italiano
CollaboratorUNKNOWN
Abteilung für Neuropsychologie, Klinik für Neurologie, Universitätsspital Zürich
CollaboratorUNKNOWN
Département des Neurosciences cliniques, Service de Neurochirurgie, CHUV, Lausanne
CollaboratorUNKNOWN
Département des Neurosciences cliniques, Service de Neurologie, CHUV, Lausanne
CollaboratorUNKNOWN
Département des Neurosciences cliniques, Service de Neurologie, Hôpitaux Universitaires de Genève
CollaboratorUNKNOWN
Swiss SOS Study Group
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

For part 1 of the study: Participants fulfilling all of the following inclusion criteria are eligible for the study: * Consent of the patient or consent of patient's next of kin (plus consent of an independent physician if patient is unable to consent) * Aneurysmal SAH * Age: ≥18 * Time of aSAH known (IMPORTANT: at least approximated. Time of aSAH refers to the bleed that lead to hospital admission; warning leaks in the patient history are not considered aSAH in this context) * Complete aneurysm occlusion therapy within 48h after aSAH * Glasgow coma scale (GCS) ≥ 13 points at time point 48h - 72h after aSAH * Fluent language skills in either English, German, French, or Italian For part 2 of the study: Participants fulfilling all of the following inclusion criteria are eligible for the study: * Consent of the patient or consent of patient's next of kin (plus consent of an independent physician if patient is unable to consent) * Age: ≥18 * Acute brain injury that requires a in-patient treatment, e.g. for (surgical) treatment of a brain tumor, a cerebral hemorrhage, a hydrocephalus, stroke, or traumatic brain injury, with stable neurological and general health status * Glasgow coma scale (GCS) ≥ 13 points * Fluent language skills in either English, German, French, or Italian

Exclusion criteria

For part 1 of the study: The presence of any one of the following

Design outcomes

Primary

MeasureTime frameDescription
Neuropsychological deterioration on the MoCA3 months after Subarachnoid HemorrhageThe primary endpoint is the in-subject difference of the MoCA before (48-72h after aSAH) and after the active phase of DCI (3 months after aSAH) between patients with and without DCI. The MoCA scores will be assessed by a neuropsychologist, not involved in the treatment of the patient and unaware of the patient's study group assignment (DCI vs. non-DCI).

Secondary

MeasureTime frameDescription
Correlation between MoCA and CT-imagingUp to 72 hours after Subarachnoid HemorrhageCorrelation of the MoCA at 48-72h with the ASPECTS score for ischemic lesions on the CT-scan at 24-72h
Shunt dependency (ventriculo-peritoneal or ventriculo-atrial shunt)3 months after Subarachnoid HemorrhageWill be assessed by a neuropsychologist, not involved in the treatment of the patient and unaware of the patient's study group assignment (DCI vs. non-DCI)
Home time3 months after Subarachnoid HemorrhageLength of time (in days) spent in own home or relative's home since Subarachnoid Hemorrhage. Will be assessed by a neuropsychologist, not involved in the treatment of the patient and unaware of the patient's study group assignment (DCI vs. non-DCI)
Minimum Clinically Important Difference (MCID) of the MoCAUp to 3 months after Subarachnoid HemorrhageThe MCID in patients with aneurysmal Subarachnoid Hemorrhage is determined using three different anchor-based approaches (using the GCS and NIHSS as anchors), namely the average change approach, minimum detectable change approach, and the change difference approach.
Neuropsychological deterioration on the MoCAUp to 28 days after Subarachnoid Hemorrhage (directly after the DCI phase)As for the primary outcome, the MoCA at 14-28 days after aSAH will be assessed by a neuropsychologist, not involved in the treatment of the patient and unaware of the patient's study group assignment (DCI vs. non-DCI)
Neuropsychological outcomeUp to 3 months after Subarachnoid HemorrhageAbsolute results of the MoCA at 48-72h, 14-28 days and 3 months in patients that develop and those that do not develop DCI
Reliability of the MoCA in patients with acute brain injuryUp to 1 month following acute brain injuryReliability of the MoCA when tested in a (busy) intermediate care (IMC)/intensive care unit (ICU), as compared to the testing in a (quiet) setting in patients with acute brain injury.
Test-retest reliability of the MoCA in patients with acute brain injuryUp to 1 month following acute brain injuryTest-retest reliability of the MoCA in patients with acute brain injury, tested two consecutive times with the MoCA (within 36 hours).
Dependency/Mortality3 months after Subarachnoid HemorrhageWill be assessed by a neuropsychologist, not involved in the treatment of the patient and unaware of the patient's study group assignment (DCI vs. non-DCI) based on the mRS at 3 months, where modified Rankin Scale (mRS) 4 and 5 is considered as dependency, and mRS 6 is considered dead
Health-related quality of life (HRQoL)3 months after Subarachnoid HemorrhageWill be assessed by a neuropsychologist, not involved in the treatment of the patient and unaware of the patient's study group assignment (DCI vs. non-DCI) using the Euro-Qol (EQ-5D)

Other

MeasureTime frameDescription
Outcomes in patiens treated surgically vs. endovascularly (aneurysm occlusion)Up to 3 months after Subarachnoid HemorrhageOutcomes 1, 2, 3 and 9-12 will be compared between patients that are treated surgically or endovascularly up to 3 months after Subarachnoid Hemorrhage.
Random number generationUp to 1 month following acute brain injuryRandom number generation, as a test of frontal executive functions in patients with acute brain injury will be assessed using the mental dice task by a neuropsychologist not involved in the treatment of the patient.
Outcomes in patients with hydrocephalus vs. without hydrocephalusUp to 3 months after Subarachnoid HemorrhageOutcomes 1, 2, 3 and 9-12 will be compared between patients that develop or do not develop hydrocephalus up to 3 months after Subarachnoid Hemorrhage.

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026